CBD Promoted as Breakthrough Treatment at 32ND International Epilepsy Congress
The 32ND International Epilepsy Congress was held in Barcelona, Spain, this past week, and CBD products were a prominent part of the conversation throughout the event.
Taking place from September 2-6, the International Epilepsy Congress gives medical professionals from around the world the chance to speak with the field’s foremost minds and to attend focused presentations revealing various aspects of epilepsy research and the development of treatment options.
Epilepsy continues to prove to be a difficult medical condition to treat. Epilepsy affects an estimated 1.3 million to 2.8 million Americans. Nearly one-third of those patients suffer from seizures that are resistant to traditional anti-epilepsy treatments. As health specialists struggle to adequately control their patients seizures with traditional methods, study after study has demonstrated the efficacy of CBD against epilepsy.
A study published in the New England Journal of Medicine this past summer showed CBD to reduce seizure frequency by 39 percent in Dravet syndrome patients. Earlier in the spring, a study published in Epilepsy & Behavior recorded a reduction of seizures in 86 percent of the patients in the study. Similarly, a study conducted on adult epilepsy patients found the use of CBD lowered seizure frequency in 9 out of 10 patients who participated.
In light of this recent research, the epilepsy community and the doctors who treat them are turning to CBD more and more, giving CBD oil products an important place at the International Epilepsy Congress.
On the second day of the event, Dr. Garza presented his recent study using RSHO-X™, a THC-free CBD oil, as a method of treatment for Lennox-Gastaut Syndrome (LGS), a severe form of pediatric epilepsy.
In the 39 patients who participated in the study, an 84% average reduction in motor seizures were experienced; 53% of patients reported better than a 75% reduction in seizures; and 17% reported a complete elimination of all seizures over a 4-month period.
Results like this have made CBD a central topic at events like last week’s International Epilepsy Congress in Barcelona. There is a growing desire for CBD oil that is driving a cultural shift in the perception of cannabinoids and their therapeutic potential in Spain, the EU, and around the world.
You can learn more about CBD, epilepsy, and more events like this on our education page.
Originally published on medicalmarijuanainc.com
